ProMIS Neurosciences Ratio court
Quel est le Ratio court de ProMIS Neurosciences?
Le Ratio court de ProMIS Neurosciences, Inc. est 3.26
Quelle est la définition de Ratio court?
Le ratio court des actions vendues est le nombre d'actions vendues à découvert divisé par le volume quotidien moyen.
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Ratio court des entreprises dans Health Care secteur sur TSX par rapport à ProMIS Neurosciences
Que fait ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Entreprises avec ratio court similaire à ProMIS Neurosciences
- Arconic a Ratio court de 3.25
- Nebius N.V a Ratio court de 3.25
- Gigcapital2 Inc a Ratio court de 3.25
- Genuine Parts Co a Ratio court de 3.25
- Immersion Corp a Ratio court de 3.25
- Ecopetrol SA a Ratio court de 3.25
- ProMIS Neurosciences a Ratio court de 3.26
- Antero Resources Corp a Ratio court de 3.27
- Artelo Biosciences a Ratio court de 3.27
- Artelo Biosciences a Ratio court de 3.27
- PGT Innovations a Ratio court de 3.27
- Masimo Corp a Ratio court de 3.27
- Primaris properties including all of H&R REIT's enclosed malls a Ratio court de 3.27